CASE STUDY World-first clinical trial improves patient outcomes for kidney transplants
Dr Michael Collins
Royal Adelaide Hospital
Filmed August 2023
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Around one in three people who receive a kidney transplant suffer delayed graft function, which means the transplant doesn’t work immediately and they require dialysis.
The lead-author of the study, was Royal Adelaide Hospital Nephrologist and University of Adelaide researcher, Dr Michael Collins.
During the four-year study, fluids were trialled in 808 patients with kidney failure, who received a kidney transplant from a deceased organ donor at the RAH and 15 other hospitals in Australia and New Zealand.
Researchers at the University of Adelaide and University of Sydney, found 30 per cent of participants who received Plasma-Lyte 148 needed dialysis after transplant, compared with 40 per cent of participants who received saline.
The results of the study are now being used to improve the health of kidney transplant patients in Australia and New Zealand and it is likely that practice will change at transplant units around the world.
You Might also like
-
Health and economic burden of interstitial lung diseases
Dr Cox’s main research interests focus on respiratory diseases and primarily on the economic burden and economic evaluation of interventions and treatments for their management. She earned her PhD from the University of Tasmania where her doctoral research examined the health and economic burden of idiopathic pulmonary fibrosis (IPF) in Australia, one component of the NHMRC Centre for Research Excellence for Pulmonary Fibrosis, a national project implemented alongside the Australian IPF Registry and the Lung Foundation Australia. This research provided the first epidemiological profile and first costing estimates of the economic burden of the disease in Australia, providing essential evidence for health service reimbursement policies.
-
RESEARCH IMPACT: 35 years of kids’ health research
The Kids Research Institute Australia is one of the largest and most successful medical research institutes in Australia. The Institute has created a blueprint that brings together community, researchers, practitioners, policy makers and funders, who share our vision to improve the health and wellbeing of children through excellence in research. In November 2025, The Kids Research Institute Australia celebrated 35 years of bold ideas, groundbreaking research, and the people who find answers to the big questions about better health outcomes for children and families.
-
Benefits of prehabilitation ahead of surgery
Dr Matthew Wallen PhD, AES, AEP is a Senior Research Fellow in Cancer Survivorship, the Deputy Lead of the Cancer Survivorship Program, and a Senior Lecturer in Exercise Science and Clinical Exercise Physiology within the College of Nursing and Health Sciences at Flinders University, in South Australia. His clinical interest focuses on improving outcomes for people requiring major surgery, specifically (1) lifestyle interventions, including exercise, nutritional, and psychological support to improve the health and wellbeing of people prior to surgery, termed ‘prehabilitation’, (2) novel physical function assessments aimed at identifying people at risk of treatment-related complications, and (3) implementation of new models of care in cancer.